Applied BioMath, LLC to sponsor and moderate at Cancer Advance Boston 2016

Applied BioMath (, the industry-leader in applying mechanistic modeling to drug development, today announced that they will sponsor, moderate, and participate in Cancer Advance Boston 2016.    Cancer Advance, being held April 4-5 at Harvard Medical School, brings together distinguished cancer experts from academia and industry, alongside the people who help turn discoveries into therapies for a high-energy, uniquely interactive meeting focused on the latest in cancer research. 

Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath, will provide opening remarks as well as moderate a Novel Therapeutic Modalities Panel, which focuses on innovative approaches in cancer research.    Dr. Burke brings a breadth of experience and appreciation for innovative approaches to this panel, as he has spent over a decade pioneering the application of mechanistic modeling in drug R&D in industry.  As a testament to the impact that such innovative approaches have on cancer R&D, following his participation in Cancer Advance Boston, Dr. Burke will present Applied BioMath's recent work in immuno-oncology at the American Association of Cancer Research (AACR) Annual Meeting.   Dr. Burke’s poster will focus on quantitative systems pharmacology modeling and analysis, which provided biological insights into anti-PD-1 dosing and predicted optimal PD-1 x TIM-3 therapeutic properties for bispecifics and fixed dose combinations in immuno-oncology.

 “I am privileged to be a part of such a distinguished meeting of cancer researchers.   I look forward to sharing, discussing, and learning about recent advances in this important field.”

Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath 

View Full Press Release